SCHEMBL4568263

SCHEMBL4568263

FC(F)(F)c1cc2[nH]c(-c3ccccc3)cc2cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
CYP19A1 P11511 4/20 0.54
KDM4E B2RXH2 4/20 0.54
MEN1 O00255 3/20 0.54
MAPT P10636 3/20 0.54
KMT2A Q03164 3/20 0.54
ALDH1A1 P00352 3/20 0.54
LMNA P02545 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CASP3 P42574 2/20 0.44
SENP8 Q96LD8 2/20 0.44
SENP7 Q9BQF6 2/20 0.44
SENP6 Q9GZR1 2/20 0.44
HPGD P15428 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568268 0.83 NPC1 (0.50) NPC1RAB9ACYP19A1KDM4EMEN1
SCHEMBL10412899 0.82 NPC1 (0.66) NPC1RAB9ACYP19A1KDM4EMEN1
SCHEMBL4568262 0.82 NPC1 (0.49) NPC1RAB9ACYP19A1KDM4EMEN1
SCHEMBL12124985 0.78 NPC1 (0.75) NPC1RAB9ACYP19A1KDM4EMEN1
SCHEMBL4568264 0.76 ALDH1A1 (0.58) NPC1RAB9ACYP19A1KDM4EMEN1
SCHEMBL4884700 0.73 NPC1 (0.58) NPC1RAB9ACYP19A1KDM4EMEN1
SCHEMBL4568274 0.73 NPC1 (0.58) NPC1RAB9ACYP19A1KDM4EMEN1
SCHEMBL15058606 0.73 CYP19A1 (0.58) NPC1RAB9ACYP19A1KDM4EMEN1
SCHEMBL22747185 0.71 GPR35 (0.51) KDM4EMAPTALDH1A1LMNAHPGD
SCHEMBL6117859 0.70 MEN1 (1.00) NPC1RAB9ACYP19A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R NPC1 1150/4885RAB9A 1646/4885CYP19A1 1262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.